

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/657,363
	<b>Filing Date</b>	September 8, 2003
	<b>First Named Inventor</b>	Young et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Hill, Myron G.
	<b>Attorney Docket No.</b>	10271-159-999

U.S. PATENT DOCUMENTS					
*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	D01	09/724,396	11-28-2000	Young	
	D02	2001-0026798	10-04-2001	Koenig	
	D03	2001-0034062	10-25-2001	Koenig	
	D04	2002-0001798	01-03-2002	Bram et al.	
	D05	2002-0004046	01-10-2002	Johnson	
	D06	2002-0018780	02-14-2002	Koenig	
	D07	2002-0051787	05-02-2002	Prince	
	D08	2002-0098189	07-25-2002	Young et al.	
	D09	2002-0102257	08-01-2002	Johnson	
	D10	2004-0005323	01-08-2004	Brams	
	D11	2004-0005324	01-08-2004	Pilkington et al.	
	D12	2004-0076631	04-22-2004	Brams et al.	
	D13	2005-0002926	01-06-2005	Young et al.	
	D14	4,800,078	01-24-1989	Prince et al.	
	D15	5,223,409	06-29-1993	Ladner et al.	
	D16	5,290,540	03-01-1994	Prince et al.	
	D17	5,403,484	05-04-1995	Ladner et al.	
	D18	5,496,703	03-05-1996	Babish et al.	
	D19	5,534,411	07-09-1996	Weltzin et al.	
	D20	5,571,698	11-05-1996	Ladner et al.	
	D21	5,667,988	09-16-1997	Barbas et al.	
	D22	5,762,905	06-09-1998	Burton et al.	
	D23	5,811,524	09-22-1998	Brams et al.	
	D24	5,840,298	11-24-1998	Brams et al.	
	D25	5,866,125	02-02-1999	Brams et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

NYI-4121260v4

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/657,363
	<b>Filing Date</b>	September 8, 2003
	<b>First Named Inventor</b>	Young et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Hill, Myron G.
	<b>Attorney Docket No.</b>	10271-159-999

U.S. PATENT DOCUMENTS					
*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	D26	5,939,068	08-17-1999	Brams et al.	
	D27	5,955,364	09-21-1999	Brams et al.	
	D28	5,958,765	09-28-1999	Brams et al.	
	D29	6,117,980	09-12-2000	Gonzalez et al.	
	D30	6,413,771	07-02-2002	Brams et al.	
	D31	6,565,849	05-20-2003	Koenig	
	D32	6,572,856	06-03-2003	Taylor et al.	
	D33	6,685,942	02-03-2004	Burton et al.	
	D34	6,818,216	11-16-2004	Young et al.	
	D35	6,855,493	02-15-2005	Young et al.	
	D36	7,179,900	02-20-2007	Young et al.	
	D37	7,208,162	04-24-2007	Prince et al.	
	D38	7,229,619	06-12-2007	Young et al.	
	D39	7,323,172	01-29-2008	Young et al.	

FOREIGN PATENT DOCUMENTS						
*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	E01	AU 713113	11-25-1999	MedImmune Inc. (US)		
	E02	CA 2,197,684	10-31-2000	MedImmune Inc. (US)		
	E03	EP 0327378	12-11-1996	Univ. Columbia, Becton Dickinson Co. (US)		
	E04	EP 0368684	05-16-1990	Medical Res Council (GB)		
	E05	EP 0671927	09-20-1995	Scripps Research Inst (US); US Health (US)		
	E06	EP 0699756	03-06-1996	Squibb Bristol Myers Co.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

NYI-4121260v4

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/657,363
	<b>Filing Date</b>	September 8, 2003
	<b>First Named Inventor</b>	Young et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Hill, Myron G.
	<b>Attorney Docket No.</b>	10271-159-999

FOREIGN PATENT DOCUMENTS						
*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	E07	FR 2758331	07-17-1998	Univ Bourgogne (FR)		
	E08	JP1268646A	10-26-1989	Meiji Milk Prod Co Ltd		
	E09	WO 92/19244	11-12-1992	Jackson H M Found Military Med		
	E10	WO 93/15199	08-05-1993	Rhone Poulenc Rorer SA (FR)		
	E11	WO 94/06448	03-31-1994	Scripps Research Inst		
	E12	WO 94/29351	12-22-1994	Celltech Ltd.		
	E13	WO 96/40252	12-19-1996	IDEC Pharma Corp.		
	E14	WO 98/33919	08-06-1998	Ixsys Inc.		
	E15	WO 01/55217	08-02-2001	Medimmune Inc.		
	E16	WO 01/64751	09-07-2001	Medimmune Inc.		
	E17	WO 02/060919	12-12-2001	Medimmune Inc. (US)		
	E18	WO 04/016750	02-26-2004	Macrogenics, Inc.		
	E19	WO 04/083373	09-30-2004	Newcastle Univ. Ventures Limited et al.		
	E20	WO 06/034292	03-30-2006	Medimmune Inc.		

NON PATENT LITERATURE DOCUMENTS			
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	F01	ABMAN et al., 1988, "Role of Respiratory Syncytial Virus in Early Hospitalizations for Respiratory Distress of Young Infants With Cystic Fibrosis", J Pediatr. 113(5):826-30	
	F02	ANDERSON et al., 1985, "Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay," J. Clin. Microbiol. 22:1050-1052	
	F03	ARBIZA et al., "Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus," J. Gen. Virol. 73: 2225-2234 (1992)	
	F04	BARBAS et al., "Selection and evolution of high-affinity human anti-viral antibodies," Trends Biotech. 14(7):230-234 (1996)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

NYI-4121260v4

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/657,363
	<b>Filing Date</b>	September 8, 2003
	<b>First Named Inventor</b>	Young et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Hill, Myron G.
	<b>Attorney Docket No.</b>	10271-159-999

NON PATENT LITERATURE DOCUMENTS			
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	F05	BEELER et al., 1989, "Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus: Effect of Mutation Upon Fusion Function", J Virol. 63(7):2941-50	
	F06	BODER et al., 2000, "Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity," Proc. Natl. Acad. Sci. U. S. A. 97(20):10701-5	
	F07	BOECKH et al., 2001, "Phase I Evaluation of the Respiratory Syncytial Virus-Specific Monoclonal Antibody Palivizumab in Recipients of Hematopoietic Stem Cell Transplants." J. of Infect. Dis. 184:350-354.	
	F08	CHANOCK et al., "Respiratory syncytial virus," Viral Infections of Humans, Epidemiology and Control, 3rd Evans, ed., A.S. Chapter 20:525-544 (1989)	
	F09	CHMURA et al., 2001, "Antibodies with infinite affinity." Proc. Natl. Acad. Sci. U.S.A. 98(15):8480-8484	
	F10	CHOWDHURY et al., 2005, "Tailor-made antibody therapeutics." Methods 36: 11-24.	
	F11	CONRAD et al., 1987, "Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic," Pediatr. Infect. Dis. J. 6(2):152-158	
	F12	CROWE et al., 1998, "Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein," Virology.252(2):373-5	
	F13	DALL'ACQUA, 2002, "Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences." J. of Immunol. 169: 5171-5180.	
	F14	DELAGRAVE et al., 1999, "Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus". Protein Eng. 12(4):357-62	
	F15	EVANS et al., eds., 1989, Viral Infections of Humans: Epidemiology and Control, 3 <sup>rd</sup> ed., Plenum Medical Book, New York, pp. 525-544	
	F16	FALSEY et al., 1991, "Noninfluenza Respiratory Virus Infection in Long-Term Care Facilities", Infect Control Hosp Epidemiol. 12(10):602-8	
	F17	FEIGEN et al., 1987, Textbook of Pediatric Infectious Diseases, WB Saunders, Philadelphia, pp. 1653-1675	
	F18	FIELDS et al., 1996, "Crystal Structure of the V-alpha domain of a T cell antigen receptor," Immunotechnology 2(4):270	
	F19	GARCIA-BARRENO, B. et al., "Marked Differences in the Antigenic Structure of Human Respiratory Syncytial Virus F and G Glycoproteins," J. Virology. 925-932 (1989)	
	F20	GILCHRIST, et al. 1994 "National surveillance for respiratory syncytial virus, United States, 1985-1990," J. Infect. Dis. 170:986-990	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

NYI-4121260v4

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/657,363
<b>Filing Date</b>	September 8, 2003
<b>First Named Inventor</b>	Young et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Hill, Myron G.
<b>Attorney Docket No.</b>	10271-159-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	F21	GLEZEN et al., 1981, "Risk of Respiratory Syncytial Virus Infection for Infants From Low-Income Families in Relationship to Age, Sex, Ethnic Group, and Maternal Antibody Level", J Pediatr. 98(5):708-15	
	F22	GROOTHUIS et al., 1988, "Respiratory Syncytial Virus Infection in Children with Bronchopulmonary Dysplasia", Pediatrics. 82(2):199-203	
	F23	GROOTHUIS et al., 1993, "Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-risk Infants and Young Children", The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 329(21):1524-30	
	F24	HACKING et al., 2002, "Respiratory syncytial virus--viral biology and the host response," J. Infection 45:18-24	
	F25	HALL et al., 1975, "Nosocomial respiratory syncytial virus infections," N. Engl. J. Med. 293(26):1343-1346	
	F26	HALL et al., 1979, "Neonatal Respiratory Syncytial Virus Infection", N Engl J Med. 300(8):393-6	
	F27	HALL et al., 1983, "Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study," N. Engl. J. Med. 308(24):1443-1447	
	F28	HALL et al., 1985, "Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease," JAMA 254(21):3047-3051	
	F29	HALL, 1987, "Respiratory syncytial virus", Textbook of Pediatric Infectious Diseases, Feigin and Cherry, eds., WB Saunders, Philadelphia, 1653-1676	
	F30	HALL, C.B., 1993, Respiratory Syncytial : What We Know Now, Contemp. Pediatrics, 10: 92-110	
	F31	HALL et al., eds., 1995, Principles and Practice of Infectious Diseases 4 <sup>th</sup> ed., Churchill Livingstone, New York, pp. 1501-1519	
	F32	HEARD et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45	
	F33	HEFTA et al, 1998, "Kinetic and affinity constants of epitope specific anti-carcinembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs," Immunotechnology 4:49-57	
	F34	HEMMING et al., 1985, "Studies of Passive Immunotherapy for Infections of Respiratory Syncytial Virus in the Respiratory Tract of a Primate Model", J Infect Dis. 152(5):1083-7	
	F35	HEMMING et al., 1986, "Immunoglobulins in respiratory syncytial virus infections," Clinical Use of Intravenous Immunoglobulins, Morell and Nydegger., eds., Academic Press, London, pp. 285-294	
	F36	HENDERSON et al., 1979, "Respiratory Syncytial Virus Infections, Reinfections and Immunity. A Prospective, Longitudinal Study in Young Children", N Engl J Med. 300(10):530-4	

NYI-4121260v4

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/657,363
	<b>Filing Date</b>	September 8, 2003
	<b>First Named Inventor</b>	Young et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Hill, Myron G.
	<b>Attorney Docket No.</b>	10271-159-999

NON PATENT LITERATURE DOCUMENTS			
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	F37	HERTZ et al., 1989, "Respiratory Syncytial Virus-Induced Acute Lung Injury in Adult Patients With Bone Marrow Transplants: a Clinical Approach and Review of the Literature", Medicine (Baltimore). 68(5):269-81	
	F38	KIM et al., 1969, "Respiratory Syncytial Virus Disease in Infants Despite Prior Administration of Antigenic Inactivated Vaccine", Am J Epidemiol. 89(4):422-34	
	F39	KUNKEL et al., 1987, "Rapid and efficient site-specific mutagenesis without phenotypic selection," Methods Enzymol. 154:367-382	
	F40	LAM et al., 1997, "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery", Proc. Int'l. Symp. Control Rel. Bioact. Mater. 24:759-760	
	F41	LAMPRECHT et al., 1976, "Role of Maternal Antibody in Pneumonia and Bronchiolitis Due to Respiratory Syncytial Virus", J Infect Dis. 134(3):211-7	
	F42	LANDRY et al., "Evaluation of reconstituted lyophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Tuesday, Infect. Dis. 166A: 969	
	F43	LoBUGLIO et al., 1989, "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response," Proc. Natl. Acad. Sci. USA 86(11):4220-4224	
	F44	MacDONALD et al., 1982, "Respiratory Syncytial Viral Infection in Infants With Congenital Heart Disease", N Engl J Med. 307(7):397-400	
	F45	MALLEY et al., 1998, "Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein." J. of Infect. Dis. 178:1555-1561.	
	F46	MARKS et al., 1992, "By-passing immunization: building high affinity human antibodies by chain shuffling," Biotechnology (N Y) 10(7):779-83	
	F47	MCARTHUR-VAUGHAN et al., 2002, "A rhesus monkey model of respiratory syncytial virus infection," J. Med. Primatol. 31(2):61-73	
	F48	MEDIMMUNE, INC. (MEDI) Release: Numax achieves primary endpoint in preliminary analysis of data from comparative phase 3 trial with Synagis (Nov. 6, 2006) BioSpace Beat, biospace.com ( <a href="http://www.biospace.com/news_story.aspx?StoryID=36114&amp;full=1">www.biospace.com/news_story.aspx?StoryID=36114&amp;full=1</a> )	
	F49	MEDIMMUNE, INC.'s (MEDI) phase I Numax study shows potential to reduce RSV disease in upper airway of children." (Spt. 1, 2005) BioSpace Beat, Biospace.com ( <a href="http://www.biospace.com/news_story.aspx?StoryID=21014020">www.biospace.com/news_story.aspx?StoryID=21014020</a> )	
	F50	MEDIMMUNE, INC., 1999, "SYNAGIS™. package insert", revised Dec. 2, 1999	
	F51	MEDIMMUNE, SYNAGIS™, 2002, package insert, revised Oct. 23, 2002.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

NYI-4121260v4

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/657,363
	<b>Filing Date</b>	September 8, 2003
	<b>First Named Inventor</b>	Young et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Hill, Myron G.
	<b>Attorney Docket No.</b>	10271-159-999

NON PATENT LITERATURE DOCUMENTS			
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	F52	MEISSNER <i>et al.</i> , "Safety and Pharmacokinetics of an Intramuscular Monoclonal Antibody (SB 209763) Against Respiratory Syncytial Virus (RSV) in Infants and Young Children at Risk for Severe RSV Disease", <i>Antimicrob Agents Chemother</i> 43:1183-1188 (1999)	
	F53	Motavizumab vs. palivizumab for RSV infections in infants (Nov. 11, 2006) Inpharma Vol. 1 No. 1563, page 5	
	F54	MURPHY et al., 1988, "Passive Transfer of Respiratory Syncytial Virus (RSV) Antiserum Suppressed The Immune Response to the RSV Fusion (F) and Large (G) Glycoproteins Expressed By Recombinant Vaccinia Viruses", <i>J Virol.</i> 62(10):3907-10	
	F55	MURPHY et al., 1991, "Effect of Passive Antibody on the Immune Response of Cotton Rats to Purified F and G HG Glycoproteins of Respiratory Syncytial Virus (RSV)", <i>Vaccine.</i> 9(3):185-9	
	F56	NAVAS et al., 1992 , "Improved Outcome of Respiratory Syncytial Virus Infection in a High-Risk Hospitalized Population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada", <i>J Pediatr.</i> 121(3):348-54	
	F57	NGUYEN et al., 2000 "Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries," <i>Clin. Exp. Immunol.</i> 122:85-93	
	F58	PALOMO et al., "Induction of a Neutralizing Immune Response to Human Respiratory Syncytial Virus with Anti-Idiotypic Antibodies" <i>J. Virology</i> 64(9): 4199-4206 (1990)	
	F59	Physician's Desk Reference, 2001, 55 <sup>th</sup> ed. p. 1863-1864	
	F60	PRINCE et al., 1983, "Mechanisms of Immunity to Respiratory Syncytial Virus in Cotton Rats", <i>Infect Immun.</i> 42(1):81-7	
	F61	PRINCE et al., 1985, "Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virus Infection in the Cotton rat", <i>Virus Res.</i> 3(3):193-206	
	F62	PRINCE et al., 1990, "Mechanism of Antibody-mediated Viral Clearance in Immunotherapy of Respiratory Syncytial Virus Infection of Cotton Rats", <i>J Virol.</i> 64(6):3091-2	
	F63	PRINCE et al., 2000, "Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in a Cotton Rat Model with Systematically Administered Monoclonal Antibody (Palivizumab) and Glucocorticosteroid," <i>J Inf Diseases</i> 182:1326-1330	
	F64	PRINCE (2001) "An update on respiratory syncytial virus antiviral agents." <i>Expert Opin Investig Drugs.</i> 10(2):297-308.	
	F65	PRINCE, 1975, "The Pathogenesis of Respiratory Syncytial Virus Infection in Infant Ferrets" Ph.D. Dissertation, University of California-Los Angeles	
	F66	ROGUSKA et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 91(3):969-973 (1994)	

NYI-4121260v4

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/657,363
	<b>Filing Date</b>	September 8, 2003
	<b>First Named Inventor</b>	Young et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Hill, Myron G.
	<b>Attorney Docket No.</b>	10271-159-999

<b>NON PATENT LITERATURE DOCUMENTS</b>			
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	F67	SAEZ-LLORENS et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstract in Non HIV virology, ICAAC Toronto	
	F68	SAEZ-LLORENS et al., 1998, "Safety and Pharmacokinetics of an Intramuscular Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature infants, and infants with Bronchopulmonary Dysplasia", The MEDI-493 Study Group, Pediatric Infect Dis J. 17(9):787-91	
	F69	SAHAGAN et al., 1986, "A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen," J. Immunol. 137(3):1066-1074	
	F70	SAKURAI et al., 1999, "Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for submit vaccines." J Virol. 73(4):2956-2962	
	F71	SCHIER et al., 1996, "Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection." J Mol Biol. 255(1):28-43	
	F72	SMITH et al., 1991, "A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection", N Engl J Med. 325(1):24-9	
	F73	SORBERA et al., 1998, "Palivizumab," Drugs Data Report 20:702-703	
	F74	SORBERA et al., 1998, "Palivizumab," Drugs of the Future 23:970-976	
	F75	STEPLEWSKI et al., 1988, "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," Proc. Natl. Acad. Sci. USA 85(13):4852-4856	
	F76	SUBRAMANIAN et al., "Safety, Tolerance and Pharmacokinetics of a Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia", Pediatric Infect Dis J. 17:110-115	
	F77	SUBRAMANIAN et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session infect. dis. 130A:768	
	F78	SUN et al., 1987, "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A," Proc. Natl. Acad. Sci. USA 84(1):214-218	
	F79	TAKEDA et al., 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314(6010):452-454	
	F80	The Impact-RSV Study Group, "Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants." Pediatrics. 1998 Sep;102(3 Pt 1):531-537	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

NYI-4121260v4

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/657,363
	<b>Filing Date</b>	September 8, 2003
	<b>First Named Inventor</b>	Young et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Hill, Myron G.
	<b>Attorney Docket No.</b>	10271-159-999

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	F81	THOMPSON et al., 1996, "Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity," J. Mol. Biol. 256(1):77-88	
	F82	VAN DER MERWE et al., 1993, "Affinity and kinetic analysis of the interaction of the cell adhesion molecules rat CD2 and CD48," EMBO J. 12(13):4945-4954	
	F83	VAN DER MERWE et al., 1994, "Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59," Biochemistry 33(33):10149-10160	
	F84	VANCOTT et al., 1994, "Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1," J. Immunol. 153(1):449-59	
	F85	WALSH et al., 1987, "Immunization with Glycoprotein Subunits of Respiratory Syncytial Virus to Protect Cotton Rats Against Viral Infection", J Infect Dis. 155(6):1198-204	
	F86	WELTZIN et al., 1994, "Intranasal Monoclonal Immunoglobulin A against Respiratory Syncytial Virus Protects against Upper and Lower Respiratory Tract Infections in Mice." Anitmicro Agents & Chemo. 38(12):2785-2791.	
	F87	WELTZIN et al., 1996, "Intranasal Monoclonal IgA Antibody to Respiratory Syncytial Virus Protects Rhesus Monkeys against Upper and Lower Tract Infection." J. of Infect Dis. 174:256-241.	
	F88	WU et al., 2002, "Tailoring Kinetics of Antibodies Using Focused Combinatorial Libraries" chapter 13 from <i>Methods in Molecular Biology</i> vol. 207, Eds. Welschop and Krauss, Humana Press Inc., Totowa, NJ, pp 213-233	
	F89	WU et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an avb-specific humanized, mAb," PNAS 95:6037-6042	
	F90	WU et al., 1999, "Humanization of murine monoclonal antibody by simultaneous optimization of framework and CDR residues," J. Mol. Biol. 294(1): 151-62	
	F91	U.S. Serial No. 09/724,396 - Office Action dated 03/26/2002	
	F92	U.S. Serial No. 09/724,396 - Office Action dated 12/03/2002	
	F93	U.S. Serial No. 09/724,396 - Office Action dated 06/03/2003	
	F94	U.S. Serial No. 09/724,396 - Office Action dated 07/28/2003	
	F95	U.S. Serial No. 09/724,396 - Office Action dated 04/05/2004	
	F96	U.S. Serial No. 09/724,531 (U.S. Patent No. 7,229,619) - Office Action dated 02/21/2003	
	F97	U.S. Serial No. 09/724,531 (U.S. Patent No. 7,229,619) - Office Action dated 10/21/2003	
	F98	U.S. Serial No. 09/724,531 (U.S. Patent No. 7,229,619) - Office Action dated 06/04/2004	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

NYI-4121260v4

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered. whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/657,363
<b>Filing Date</b>	September 8, 2003
<b>First Named Inventor</b>	Young et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Hill, Myron G.
<b>Attorney Docket No.</b>	10271-159-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	F99	U.S. Serial No. 09/724,531 (U.S. Patent No. 7,229,619) - Office Action dated 02/09/2005	
	F100	U.S. Serial No. 09/724,531 (U.S. Patent No. 7,229,619) - Office Action dated 06/15/2005	
	F101	U.S. Serial No. 09/724,531 (U.S. Patent No. 7,229,619) - Office Action dated 04/04/2006	
	F102	U.S. Serial No. 09/724,531 (U.S. Patent No. 7,229,619) - Office Action dated 08/22/2006	
	F103	U.S. Serial No. 09/724,531 (U.S. Patent No. 7,229,619) - Office Action dated 01/30/2007	
	F104	U.S. Serial No. 09/996,288 (U.S. Patent No. 6,818,216) - Office Action dated 07/14/2003	
	F105	U.S. Serial No. 09/996,288 (U.S. Patent No. 6,818,216) - Office Action dated 01/29/2004	
	F106	U.S. Serial No. 09/996,288 (U.S. Patent No. 6,818,216) - Office Action dated 06/30/2004	
	F107	U.S. Serial No. 09/996,265 (U.S. Patent No. 6,855,493) - Office Action dated 08/12/2003	
	F108	U.S. Serial No. 09/996,265 (U.S. Patent No. 6,855,493) - Office Action dated 03/31/2004	
	F109	U.S. Serial No. 09/996,265 (U.S. Patent No. 6,855,493) - Office Action dated 07/13/2004	
	F110	U.S. Serial No. 10/403,180 (U.S. Patent No. 7,179,900) - Office Action dated 04/04/2005	
	F111	U.S. Serial No. 10/403,180 (U.S. Patent No. 7,179,900) - Office Action dated 10/19/2005	
	F112	U.S. Serial No. 10/403,180 (U.S. Patent No. 7,179,900) - Office Action dated 03/30/2006	
	F113	U.S. Serial No. 10/403,180 (U.S. Patent No. 7,179,900) - Office Action dated 09/06/2006	
	F114	U.S. Serial No. 10/900,230 (U.S. Publ. No. 2005/0002926) - Office Action dated 01/24/2006	
	F115	U.S. Serial No. 10/900,230 (U.S. Publ. No. 2005/0002926) - Office Action dated 06/30/2006	
	F116	U.S. Serial No. 10/900,230 (U.S. Publ. No. 2005/0002926) - Office Action dated 12/26/2006	
	F117	U.S. Serial No. 10/900,230 (U.S. Publ. No. 2005/0002926) - Office Action dated 06/27/2007	
	F118	U.S. Serial No. 10/900,230 (U.S. Publ. No. 2005/0002926) - Office Action dated 02/21/2008	
	F119	U.S. Serial No. 10/962,285 (U.S. Patent No. 7,323,172) - Office Action dated 10/26/2006	
	F120	U.S. Serial No. 10/962,285 (U.S. Patent No. 7,323,172) - Office Action dated 04/13/2007	
	F121	U.S. Serial No. 09/796,848 (U.S. Publ. No. 2002/0098189) - Office Action dated 06/18/2002	
	F122	U.S. Serial No. 09/796,848 (U.S. Publ. No. 2002/0098189) - Office Action dated 12/29/2003	
	F123	U.S. Serial No. 09/796,848 (U.S. Publ. No. 2002/0098189) - Office Action dated 10/29/2004	
	F124	U.S. Serial No. 09/796,848 (U.S. Publ. No. 2002/0098189) - Office Action dated 07/13/2005	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

NYI-4121260v4

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/657,363
<b>Filing Date</b>	September 8, 2003
<b>First Named Inventor</b>	Young et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Hill, Myron G.
<b>Attorney Docket No.</b>	10271-159-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	F125	U.S. Serial No. 09/796,848 (U.S. Publ. No. 2002/0098189) - Office Action dated 04/04/2006	
	F126	U.S. Serial No. 09/796,848 (U.S. Publ. No. 2002/0098189) - Office Action dated 07/27/2007	
	F127	U.S. Serial No. 09/796,848 (U.S. Publ. No. 2002/0098189) - Office Action dated 04/14/2008	
	F128	U.S. Serial No. 11/263,230 (U.S. Publ. No. 2006/0115485) - Office Action dated 01/09/2008	
	F129	U.S. Serial No. 11/643,982 (U.S. Publ. No. 2007/0196916) - Office Action dated 09/02/2008	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

NYI-4121260v4

<b>EXAMINER SIGNATURE</b>  <div style="text-align: center;">/Myron Hill/</div>	<b>DATE CONSIDERED</b> 12/20/2008
<small>*EXAMINER: Initial if reference considered. whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	